NBIX Neurocrine Biosciences Loading...

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
23:51
Aug 17
Jim Cramer CNBC
CNBC
Profitable company succeeding in a tough space.
Although neurological issues are a tough space, the company is profitable and does a good job with its formulations.
NBIX Neurocrine Biosciences Long 1ST — —

About NBIX Investor Commentary

Across the available history and selected sources, Buzzberg tracks NBIX (Neurocrine Biosciences) across 4 sources: 1 bullish vs 0 bearish calls from 4 authors. Historical directional balance: 14% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 7 total trade ideas tracked. Latest voices: Jim Cramer.